Newer compounds like Tirzepatide or Retatrutide, which act on multiple receptors like GLP-1 and GIP, represent the next frontier in this area, offering even more complex and powerful metabolic modulation to study alongside IGF-1 LR3's anabolic signaling
These new anti-obesity medications are associated with over 10% body weight loss known to improve many of the complications associated with obesity
Transparency and Compliance Positioning According to the company's marketing materials, "From ingredient sourcing to doorstep delivery, we prioritize high quality standards and complete transparency." The site includes detailed safety information pages, clear disclaimers about compounded medications not being FDA-approved, and accessible terms of service
Umar M, Jahangir N, Khan MF, Saeed Z, Sultan F, Sultan A